Funding
Series B · Biotech

EnteroBiotix raises £19m Series B for microbiome therapeutics

Thairm Bio and the Scottish National Investment Bank participated in the gastrointestinal therapeutics developer's financing.

Updated Oct 16, 2026By RoundOS Funding desk

EnteroBiotix raised £19 million in Series B funding on May 4, with participation from Thairm Bio and the Scottish National Investment Bank. The company develops full-spectrum microbiome therapeutics for gastrointestinal diseases, including irritable bowel syndrome.

Funding history

Series B · This round£19M

Sources

  1. EnteroBiotixprojectstartups.com
  2. tech.eu

Similar rounds

All Biotech rounds →
Guoke Brain-Computer

Beijing startup developing non-invasive wearable brain-computer interfaces that combine brain-signal detection, decoding and neural modulation.

UndisclosedSeed · Oct 23, 2026
Star Therapeutics

Biotechnology company discovering and developing antibody therapies for diseases with significant unmet need.

$200MPrivate financing · Oct 23, 2026
Pathos AI

Clinical-stage drug developer using AI to select therapeutic assets and guide oncology trials.

$237MSeries E · Oct 23, 2026
Warp Sciences

Warp Sciences combines chemistry, AI and robotics to help drug discovery teams make and test molecules in the United States.

$215MSeries A · Oct 22, 2026

Related